Perospirone

Perospirone is an atypical antipsychotic agent. It is a novel antipsychotic developed by Dainippon Sumitomo Pharma. It was approved for use in Japan in 2001. Perospirone has a high affinity for serotonin 5-HT2A receptors and dopamine D2 receptors. It also has an affinity for serotonin 5-HT1A receptors.

Etymology[edit | edit source]

The term "Perospirone" is derived from its chemical name, which is 4-[4-[4-(1-piperazinyl)-1-p-tolylbutyl]-2,6-difluorophenoxy]ethanol. The name is a combination of parts of its chemical structure and its pharmacological properties.

Pharmacology[edit | edit source]

Perospirone is classified as an atypical antipsychotic due to its unique pharmacological properties. It has a high affinity for serotonin 5-HT2A receptors and dopamine D2 receptors, which are thought to be involved in the pathophysiology of schizophrenia. Perospirone also has an affinity for serotonin 5-HT1A receptors, which may contribute to its antipsychotic and antidepressant effects.

Clinical Use[edit | edit source]

Perospirone is used in the treatment of schizophrenia. It is also used off-label for the treatment of bipolar disorder and as an adjunct in the treatment of major depressive disorder. The drug has been shown to be effective in reducing both positive and negative symptoms of schizophrenia.

Side Effects[edit | edit source]

Common side effects of perospirone include somnolence, akathisia, and hyperprolactinemia. Less common side effects include weight gain, orthostatic hypotension, and extrapyramidal symptoms. Rare but serious side effects include neuroleptic malignant syndrome and tardive dyskinesia.

See Also[edit | edit source]

Perospirone Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.